Incyte Corporation (INCY)

Market Cap	16.23B
Revenue (ttm)	4.58B
Net Income (ttm)	870.87M
Shares Out	195.28M
EPS (ttm)	4.37
PE Ratio	19.02
Forward PE	12.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,774,911
Open	85.49
Previous Close	86.17
Day's Range	82.82 - 85.51
52-Week Range	53.56 - 87.99
Beta	0.75
Analysts	Buy
Price Target	80.31 (-3.36%)
Earnings Date	Oct 28, 2025

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 4, 1993
• Employees: 2,617
• Stock Exchange: NASDAQ
• Ticker Symbol: INCY
• Website: https://www.incyte.com

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Analyst Summary

According to 20 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $80.31, which is a decrease of -3.36% from the latest price.

Price Target

$80.31

(-3.36% downside)

Analyst Consensus: Buy